Kane Biotech Announces First Quarter 2026 Financial Results

• Q1 2026 Financial Results: Kane Biotech reported a net loss of $714,827 for Q1 2026, an improvement over the prior year's loss of $1.2M, but revenue collapsed to $43,218 from $412,513 in Q1 2025.
• Financing: Completed an oversubscribed non-brokered private placement on May 26, 2026, raising $1.16 million at $0.05 per unit (23.2M units issued).
• Regulatory Milestone: Confirmed U.S. FDA 510(k) clearance for revyve Antimicrobial Skin and Wound Cleanser in February 2026, the third cleared product in the portfolio.
• Commercial Expansion: Entered distribution agreements with Marathon Medical Corporation (access to VA, DOD, IHS channels) and expanded U.S./Canada sales teams with new VP appointments.
• Cash Position: Cash balance was $395,058 as of March 31, 2026; the May financing extends liquidity significantly.

• Liquidity Extension (Positive): The primary materiality driver is the successful closing of the private placement. With operating expenses at ~$670k/quarter and cash on hand at $395k pre-financing, the company faced a near-term liquidity crunch. The $1.16M raise extends runway by approximately 2-3 quarters, mitigating immediate bankruptcy risk.
• Revenue Collapse (Negative): Revenue dropped ~90% year-over-year ($43k vs $412k). This indicates the commercial pivot is not yet generating meaningful top-line growth despite regulatory clearances. The Q4 2025 results already signaled this trend ($8k revenue), so the Q1 miss is expected but confirms a fundamental execution gap.
• Regulatory Validation (Positive): FDA clearance for the Cleanser validates the product platform, but without sales data to match, it remains an asset on paper rather than cash flow generator.
• Insider Confidence: Board Chair Philip Renaud participated in the offering, signaling management confidence in the strategy, though this is a small amount relative to total capital needs.

• Company: Kane Biotech Inc., a biotechnology company focused on wound care solutions.
• Flagship Product: revyve® Antimicrobial Wound Gel, Spray, and Cleanser.
• Technology: Thermoreversible technology designed to disrupt biofilms in chronic wounds (venous ulcers, diabetic foot ulcers).
• Regulatory Status: Products are FDA 510(k) cleared in the U.S. and Health Canada approved.
• Strategy: Pivot from animal health manufacturing to human wound care commercialization via distribution partnerships and clinical validation.